

Joseph J Eron

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4759541/publications.pdf>

Version: 2024-02-01

374
papers

41,305
citations

2970

93
h-index

2624

194
g-index

384
all docs

384
docs citations

384
times ranked

24713
citing authors

#	ARTICLE	IF	CITATIONS
1	Prevention of HIV-1 Infection with Early Antiretroviral Therapy. <i>New England Journal of Medicine</i> , 2011, 365, 493-505.	13.9	6,046
2	A Controlled Trial of Two Nucleoside Analogues plus Indinavir in Persons with Human Immunodeficiency Virus Infection and CD4 Cell Counts of 200 per Cubic Millimeter or Less. <i>New England Journal of Medicine</i> , 1997, 337, 725-733.	13.9	2,532
3	Treatment with Indinavir, Zidovudine, and Lamivudine in Adults with Human Immunodeficiency Virus Infection and Prior Antiretroviral Therapy. <i>New England Journal of Medicine</i> , 1997, 337, 734-739.	13.9	1,823
4	Antiretroviral Therapy for the Prevention of HIV-1 Transmission. <i>New England Journal of Medicine</i> , 2016, 375, 830-839.	13.9	1,282
5	Antiretroviral Treatment of Adult HIV Infection. <i>JAMA - Journal of the American Medical Association</i> , 2012, 308, 387-402.	3.8	1,239
6	Effect of Early versus Deferred Antiretroviral Therapy for HIV on Survival. <i>New England Journal of Medicine</i> , 2009, 360, 1815-1826.	13.9	986
7	Enfuvirtide, an HIV-1 Fusion Inhibitor, for Drug-Resistant HIV Infection in North and South America. <i>New England Journal of Medicine</i> , 2003, 348, 2175-2185.	13.9	884
8	Antiretroviral Treatment of Adult HIV Infection. <i>JAMA - Journal of the American Medical Association</i> , 2008, 300, 555.	3.8	846
9	Reduction of concentration of HIV-1 in semen after treatment of urethritis: implications for prevention of sexual transmission of HIV-1. <i>Lancet, The</i> , 1997, 349, 1868-1873.	6.3	805
10	Brief but Efficient: Acute HIV Infection and the Sexual Transmission of HIV. <i>Journal of Infectious Diseases</i> , 2004, 189, 1785-1792.	1.9	594
11	Initial B-Cell Responses to Transmitted Human Immunodeficiency Virus Type 1: Virion-Binding Immunoglobulin M (IgM) and IgG Antibodies Followed by Plasma Anti-gp41 Antibodies with Ineffective Control of Initial Viremia. <i>Journal of Virology</i> , 2008, 82, 12449-12463.	1.5	548
12	Treatment with Lamivudine, Zidovudine, or Both in HIV-Positive Patients with 200 to 500 CD4+ Cells per Cubic Millimeter. <i>New England Journal of Medicine</i> , 1995, 333, 1662-1669.	13.9	538
13	Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults. <i>JAMA - Journal of the American Medical Association</i> , 2016, 316, 191.	3.8	533
14	Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults. <i>JAMA - Journal of the American Medical Association</i> , 2018, 320, 379.	3.8	486
15	Antiretroviral Treatment of Adult HIV Infection. <i>JAMA - Journal of the American Medical Association</i> , 2014, 312, 410.	3.8	428
16	Effects of early versus delayed initiation of antiretroviral treatment on clinical outcomes of HIV-1 infection: results from the phase 3 HPTN 052 randomised controlled trial. <i>Lancet Infectious Diseases, The</i> , 2014, 14, 281-290.	4.6	423
17	Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trial. <i>Lancet, The</i> , 2017, 390, 1499-1510.	6.3	391
18	Precise Quantitation of the Latent HIV-1 Reservoir: Implications for Eradication Strategies. <i>Journal of Infectious Diseases</i> , 2015, 212, 1361-1365.	1.9	362

#	ARTICLE	IF	CITATIONS
19	Cabotegravir for HIV Prevention in Cisgender Men and Transgender Women. <i>New England Journal of Medicine</i> , 2021, 385, 595-608.	13.9	359
20	Detection of Acute Infections during HIV Testing in North Carolina. <i>New England Journal of Medicine</i> , 2005, 352, 1873-1883.	13.9	352
21	Maximizing sensitivity and specificity of PCR by preamplification heating. <i>Nucleic Acids Research</i> , 1991, 19, 3749-3749.	6.5	348
22	The KLEAN study of fosamprenavir-ritonavir versus lopinavir-ritonavir, each in combination with abacavir-lamivudine, for initial treatment of HIV infection over 48 weeks: a randomised non-inferiority trial. <i>Lancet, The</i> , 2006, 368, 476-482.	6.3	345
23	Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults. <i>JAMA - Journal of the American Medical Association</i> , 2020, 324, 1651.	3.8	329
24	Ombitasvir, Paritaprevir Co-dosed With Ritonavir, Dasabuvir, and Ribavirin for Hepatitis C in Patients Co-infected With HIV-1. <i>JAMA - Journal of the American Medical Association</i> , 2015, 313, 1223.	3.8	290
25	Switch to a raltegravir-based regimen versus continuation of a lopinavir-ritonavir-based regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK 1 and 2): two multicentre, double-blind, randomised controlled trials. <i>Lancet, The</i> , 2010, 375, 396-407.	6.3	276
26	Safety and Efficacy of Dolutegravir in Treatment-Experienced Subjects With Raltegravir-Resistant HIV Type 1 Infection: 24-Week Results of the VIKING Study. <i>Journal of Infectious Diseases</i> , 2013, 207, 740-748.	1.9	271
27	Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials. <i>Lancet, The</i> , 2019, 393, 143-155.	6.3	265
28	High Multiplicity Infection by HIV-1 in Men Who Have Sex with Men. <i>PLoS Pathogens</i> , 2010, 6, e1000890.	2.1	263
29	The Effect of Raltegravir Intensification on Low-level Residual Viremia in HIV-Infected Patients on Antiretroviral Therapy: A Randomized Controlled Trial. <i>PLoS Medicine</i> , 2010, 7, e1000321.	3.9	258
30	Viral burden in genital secretions determines male-to-female sexual transmission of HIV-1: a probabilistic empiric model. <i>Aids</i> , 2001, 15, 621-627.	1.0	248
31	Novel Therapies Based on Mechanisms of HIV-1 Cell Entry. <i>New England Journal of Medicine</i> , 2003, 348, 2228-2238.	13.9	243
32	A phase 2a clinical trial of molnupiravir in patients with COVID-19 shows accelerated SARS-CoV-2 RNA clearance and elimination of infectious virus. <i>Science Translational Medicine</i> , 2022, 14, eabl7430.	5.8	241
33	Potent antiretroviral treatment of HIV-infection results in suppression of the seminal shedding of HIV. <i>Aids</i> , 2000, 14, 117-121.	1.0	232
34	Rising Obesity Prevalence and Weight Gain Among Adults Starting Antiretroviral Therapy in the United States and Canada. <i>AIDS Research and Human Retroviruses</i> , 2016, 32, 50-58.	0.5	231
35	Macrophages sustain HIV replication in vivo independently of T cells. <i>Journal of Clinical Investigation</i> , 2016, 126, 1353-1366.	3.9	230
36	Simultaneous vs Sequential Initiation of Therapy With Indinavir, Zidovudine, and Lamivudine for HIV-1 Infection. <i>JAMA - Journal of the American Medical Association</i> , 1998, 280, 35.	3.8	228

#	ARTICLE	IF	CITATIONS
37	HIV-1 Expression Within Resting CD4+ T Cells After Multiple Doses of Vorinostat. <i>Journal of Infectious Diseases</i> , 2014, 210, 728-735.	1.9	223
38	ABT-378/ritonavir plus stavudine and lamivudine for the treatment of antiretroviral-naïve adults with HIV-1 infection: 48-week results. <i>Aids</i> , 2001, 15, F1-F9.	1.0	206
39	Immediate antiviral therapy appears to restrict resting CD4 ⁺ cell HIV-1 infection without accelerating the decay of latent infection. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012, 109, 9523-9528.	3.3	202
40	Long-Term Efficacy and Safety of Raltegravir Combined with Optimized Background Therapy in Treatment-Experienced Patients with Drug-Resistant HIV Infection: Week 96 Results of the BENCHMRK 1 and 2 Phase III Trials. <i>Clinical Infectious Diseases</i> , 2010, 50, 605-612.	2.9	196
41	Clinical Trial of the Anti-PD-L1 Antibody BMS-936559 in HIV-1 Infected Participants on Suppressive Antiretroviral Therapy. <i>Journal of Infectious Diseases</i> , 2017, 215, 1725-1733.	1.9	196
42	The Safety, Plasma Pharmacokinetics, and Antiviral Activity of Subcutaneous Enfuvirtide (T-20), a Peptide Inhibitor of gp41-Mediated Virus Fusion, in HIV-Infected Adults. <i>AIDS Research and Human Retroviruses</i> , 2002, 18, 685-693.	0.5	187
43	Late Presentation for Human Immunodeficiency Virus Care in the United States and Canada. <i>Clinical Infectious Diseases</i> , 2010, 50, 1512-1520.	2.9	187
44	Characterization of V3 Sequence Heterogeneity in Subtype C Human Immunodeficiency Virus Type 1 Isolates from Malawi: Underrepresentation of X4 Variants. <i>Journal of Virology</i> , 1999, 73, 6271-6281.	1.5	182
45	Cohort Profile: The North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD). <i>International Journal of Epidemiology</i> , 2007, 36, 294-301.	0.9	176
46	Raltegravir once daily or twice daily in previously untreated patients with HIV-1: a randomised, active-controlled, phase 3 non-inferiority trial. <i>Lancet Infectious Diseases</i> , The, 2011, 11, 907-915.	4.6	175
47	Association Between Efavirenz as Initial Therapy for HIV-1 Infection and Increased Risk for Suicidal Ideation or Attempted or Completed Suicide. <i>Annals of Internal Medicine</i> , 2014, 161, 1.	2.0	175
48	Cabotegravir plus rilpivirine, once a day, after induction with cabotegravir plus nucleoside reverse transcriptase inhibitors in antiretroviral-naïve adults with HIV-1 infection (LATTE): a randomised, phase 2b, dose-ranging trial. <i>Lancet Infectious Diseases</i> , The, 2015, 15, 1145-1155.	4.6	175
49	Valproic acid without intensified antiviral therapy has limited impact on persistent HIV infection of resting CD4+ T cells. <i>Aids</i> , 2008, 22, 1131-1135.	1.0	172
50	Resistance of HIV-1 to antiretroviral agents in blood and seminal plasma. <i>Aids</i> , 1998, 12, F181-F189.	1.0	167
51	Interval dosing with the HDAC inhibitor vorinostat effectively reverses HIV latency. <i>Journal of Clinical Investigation</i> , 2017, 127, 3126-3135.	3.9	165
52	Sexual transmission of HIV: infectiousness and prevention. <i>Aids</i> , 1999, 13, 155-166.	1.0	163
53	Incidence and etiology of acute renal failure among ambulatory HIV-infected patients. <i>Kidney International</i> , 2005, 67, 1526-1531.	2.6	162
54	Dual vs Single Protease Inhibitor Therapy Following Antiretroviral Treatment Failure<SUBTITLE>A Randomized Trial</SUBTITLE>. <i>JAMA - Journal of the American Medical Association</i> , 2002, 288, 169.	3.8	160

#	ARTICLE	IF	CITATIONS
55	Use of evolutionary limitations of HIV-1 multidrug resistance to optimize therapy. <i>Nature</i> , 1993, 361, 650-654.	13.7	153
56	Temporal Trends in Presentation and Survival for HIV-Associated Lymphoma in the Antiretroviral Therapy Era. <i>Journal of the National Cancer Institute</i> , 2013, 105, 1221-1229.	3.0	152
57	Antiretroviral-Drug Concentrations in Semen: Implications for Sexual Transmission of Human Immunodeficiency Virus Type 1. <i>Antimicrobial Agents and Chemotherapy</i> , 1999, 43, 1817-1826.	1.4	149
58	Splines for Trend Analysis and Continuous Confounder Control. <i>Epidemiology</i> , 2011, 22, 874-875.	1.2	148
59	Levels of HIV-1 persistence on antiretroviral therapy are not associated with markers of inflammation or activation. <i>PLoS Pathogens</i> , 2017, 13, e1006285.	2.1	147
60	Prevalence and Predictors of Substance Use Disorders Among HIV Care Enrollees in the United States. <i>AIDS and Behavior</i> , 2017, 21, 1138-1148.	1.4	145
61	HIV in body fluids during primary HIV infection: implications for pathogenesis, treatment and public health. <i>Aids</i> , 2001, 15, 837-845.	1.0	144
62	Polyclonal B Cell Differentiation and Loss of Gastrointestinal Tract Germinal Centers in the Earliest Stages of HIV-1 Infection. <i>PLoS Medicine</i> , 2009, 6, e1000107.	3.9	143
63	End-Stage Renal Disease Among HIV-Infected Adults in North America. <i>Clinical Infectious Diseases</i> , 2015, 60, 941-949.	2.9	142
64	Antiretroviral Intensification and Valproic Acid Lack Sustained Effect on Residual HIV-1 Viremia or Resting CD4+ Cell Infection. <i>PLoS ONE</i> , 2010, 5, e9390.	1.1	141
65	Real-time, Universal Screening for Acute HIV Infection in a Routine HIV Counseling and Testing Population. <i>JAMA - Journal of the American Medical Association</i> , 2002, 288, 216.	3.8	140
66	Systemically Circulating Viral and Tumor-Derived MicroRNAs in KSHV-Associated Malignancies. <i>PLoS Pathogens</i> , 2013, 9, e1003484.	2.1	140
67	Recommendations for analytical antiretroviral treatment interruptions in HIV research trials—report of a consensus meeting. <i>Lancet HIV</i> , 2019, 6, e259-e268.	2.1	139
68	Risk Factor Analyses for Immune Reconstitution Inflammatory Syndrome in a Randomized Study of Early vs. Deferred ART during an Opportunistic Infection. <i>PLoS ONE</i> , 2010, 5, e11416.	1.1	135
69	Beyond Core Indicators of Retention in HIV Care: Missed Clinic Visits Are Independently Associated With All-Cause Mortality. <i>Clinical Infectious Diseases</i> , 2014, 59, 1471-1479.	2.9	134
70	A phase II clinical study of the long-term safety and antiviral activity of enfuvirtide-based antiretroviral therapy. <i>Aids</i> , 2003, 17, 691-698.	1.0	130
71	Antiretroviral Drug Resistance in HIV-1 Infected Patients Experiencing Persistent Low-Level Viremia During First-Line Therapy. <i>Journal of Infectious Diseases</i> , 2011, 204, 515-520.	1.9	130
72	Acute HIV revisited: new opportunities for treatment and prevention. <i>Journal of Clinical Investigation</i> , 2004, 113, 937-945.	3.9	130

#	ARTICLE	IF	CITATIONS
73	Pharmacokinetics of lamivudine administered alone and with trimethoprim-sulfamethoxazole*. <i>Clinical Pharmacology and Therapeutics</i> , 1996, 59, 550-558.	2.3	128
74	Safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in low-risk HIV-uninfected individuals: HPTN 077, a phase 2a randomized controlled trial. <i>PLoS Medicine</i> , 2018, 15, e1002690.	3.9	126
75	Curing HIV: Seeking to Target and Clear Persistent Infection. <i>Cell</i> , 2020, 181, 189-206.	13.5	126
76	HIV Antigens Can Induce TGF- β 1-Producing Immunoregulatory CD8+ T Cells. <i>Journal of Immunology</i> , 2002, 168, 2247-2254.	0.4	125
77	Viremia Copy-Years Predicts Mortality Among Treatment-Naive HIV-Infected Patients Initiating Antiretroviral Therapy. <i>Clinical Infectious Diseases</i> , 2011, 53, 927-935.	2.9	122
78	Human Immunodeficiency Virus Type 1-Specific Cytotoxic T Lymphocyte Activity Is Inversely Correlated with HIV Type 1 Viral Load in HIV Type 1-Infected Long-Term Survivors. <i>AIDS Research and Human Retroviruses</i> , 1999, 15, 1219-1228.	0.5	120
79	Frequent detection of acute primary HIV infection in men in Malawi. <i>Aids</i> , 2004, 18, 517-524.	1.0	119
80	Efficacy and safety of raltegravir for treatment of HIV for 5 years in the BENCHMRK studies: final results of two randomised, placebo-controlled trials. <i>Lancet Infectious Diseases</i> , The, 2013, 13, 587-596.	4.6	119
81	CCL3L1-CCR5 genotype influences durability of immune recovery during antiretroviral therapy of HIV-1-infected individuals. <i>Nature Medicine</i> , 2008, 14, 413-420.	15.2	118
82	Quantitation of human immunodeficiency virus type 1 RNA in cell free seminal plasma: comparison of NASBA, with Amplicor, reverse transcription-PCR amplification and correlation with quantitative culture. <i>Journal of Virological Methods</i> , 1996, 60, 161-170.	1.0	116
83	Nelfinavir, Efavirenz, or Both after the Failure of Nucleoside Treatment of HIV Infection. <i>New England Journal of Medicine</i> , 2001, 345, 398-407.	13.9	116
84	Multiple V1/V2 env Variants Are Frequently Present during Primary Infection with Human Immunodeficiency Virus Type 1. <i>Journal of Virology</i> , 2004, 78, 11208-11218.	1.5	116
85	Once-daily versus Twice-daily Lopinavir/Ritonavir in Antiretroviral-naïve HIV-positive Patients: A 48-week Randomized Clinical Trial. <i>Journal of Infectious Diseases</i> , 2004, 189, 265-272.	1.9	114
86	Recurrent Signature Patterns in HIV-1 B Clade Envelope Glycoproteins Associated with either Early or Chronic Infections. <i>PLoS Pathogens</i> , 2011, 7, e1002209.	2.1	114
87	Increased Risk of Myocardial Infarction in HIV-Infected Individuals in North America Compared With the General Population. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2017, 75, 568-576.	0.9	110
88	Prevalence and Comorbidity of Psychiatric Diagnoses Based on Reference Standard in an HIV+ Patient Population. <i>Psychosomatic Medicine</i> , 2008, 70, 505-511.	1.3	109
89	Incidence and Timing of Cancer in HIV-Infected Individuals Following Initiation of Combination Antiretroviral Therapy. <i>Clinical Infectious Diseases</i> , 2013, 57, 756-764.	2.9	107
90	Prevalence and Factors Associated with Hazardous Alcohol Use Among Persons Living with HIV Across the US in the Current Era of Antiretroviral Treatment. <i>AIDS and Behavior</i> , 2017, 21, 1914-1925.	1.4	102

#	ARTICLE	IF	CITATIONS
91	Fixed-dose combination dolutegravir, abacavir, and lamivudine versus ritonavir-boosted atazanavir plus tenofovir disoproxil fumarate and emtricitabine in previously untreated women with HIV-1 infection (ARIA): week 48 results from a randomised, open-label, non-inferiority, phase 3b study. <i>Lancet HIV</i> , 2017, 4, e536-e546.	2.1	101
92	Renal safety of tenofovir alafenamide vs. tenofovir disoproxil fumarate. <i>Aids</i> , 2019, 33, 1455-1465.	1.0	99
93	Long-term safety and durable antiretroviral activity of lopinavir/ritonavir in treatment-naïve patients. <i>Aids</i> , 2004, 18, 775-779.	1.0	98
94	Resistance to HIV Integrase Strand Transfer Inhibitors Among Clinical Specimens in the United States, 2009-2012. <i>Clinical Infectious Diseases</i> , 2014, 58, 423-431.	2.9	98
95	Tail-phase safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in HIV-uninfected adults: a secondary analysis of the HPTN 077 trial. <i>Lancet HIV</i> , 2020, 7, e472-e481.	2.1	97
96	Assessing and Refining Myocardial Infarction Risk Estimation Among Patients With Human Immunodeficiency Virus. <i>JAMA Cardiology</i> , 2017, 2, 155.	3.0	96
97	No Effect of Raltegravir Intensification on Viral Replication Markers in the Blood of HIV-1-Infected Patients Receiving Antiretroviral Therapy. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2012, 59, 229-235.	0.9	95
98	Pre-Exposure Prophylaxis and Antiretroviral Resistance: HIV Prevention at a Cost?. <i>Clinical Infectious Diseases</i> , 2011, 53, 1265-1270.	2.9	94
99	Contributions of traditional and HIV-related risk factors on non-AIDS-defining cancer, myocardial infarction, and end-stage liver and renal diseases in adults with HIV in the USA and Canada: a collaboration of cohort studies. <i>Lancet HIV</i> , 2019, 6, e93-e104.	2.1	94
100	Evidence That Intermittent Structured Treatment Interruption, but Not Immunization with ALVAC-HIV vCP1452, Promotes Host Control of HIV Replication: The Results of AIDS Clinical Trials Group 5068. <i>Journal of Infectious Diseases</i> , 2006, 194, 623-632.	1.9	91
101	HIV Viral Suppression Trends Over Time Among HIV-Infected Patients Receiving Care in the United States, 1997 to 2015. <i>Annals of Internal Medicine</i> , 2018, 169, 376.	2.0	91
102	Trends and Disparities in Antiretroviral Therapy Initiation and Virologic Suppression Among Newly Treatment-Eligible HIV-Infected Individuals in North America, 2001-2009. <i>Clinical Infectious Diseases</i> , 2013, 56, 1174-1182.	2.9	90
103	Pharmacokinetics and Pharmacodynamics of Once-Daily versus Twice-Daily Raltegravir in Treatment-Naïve HIV-Infected Patients. <i>Antimicrobial Agents and Chemotherapy</i> , 2012, 56, 3101-3106.	1.4	87
104	Effects of Genital Tract Inflammation on Human Immunodeficiency Virus Type 1 V3 Populations in Blood and Semen. <i>Journal of Virology</i> , 2000, 74, 8946-8952.	1.5	85
105	Copy-Years Viremia as a Measure of Cumulative Human Immunodeficiency Virus Viral Burden. <i>American Journal of Epidemiology</i> , 2010, 171, 198-205.	1.6	85
106	Efficacy and safety of switching from boosted protease inhibitors plus emtricitabine and tenofovir disoproxil fumarate regimens to single-tablet darunavir, cobicistat, emtricitabine, and tenofovir alafenamide at 48 weeks in adults with virologically suppressed HIV-1 (EMERALD): a phase 3, randomised, non-inferiority trial. <i>Lancet HIV</i> , 2018, 5, e23-e34.	2.1	83
107	Persistent HIV-infected cells in cerebrospinal fluid are associated with poorer neurocognitive performance. <i>Journal of Clinical Investigation</i> , 2019, 129, 3339-3346.	3.9	81
108	Selective Decay of Intact HIV-1 Proviral DNA on Antiretroviral Therapy. <i>Journal of Infectious Diseases</i> , 2021, 223, 225-233.	1.9	80

#	ARTICLE	IF	CITATIONS
109	Late Entry to HIV Care Among Latinos Compared With Non-Latinos in a Southeastern US Cohort. <i>Clinical Infectious Diseases</i> , 2011, 53, 480-487.	2.9	79
110	Clonal Sequences Recovered from Plasma from Patients with Residual HIV-1 Viremia and on Intensified Antiretroviral Therapy Are Identical to Replicating Viral RNAs Recovered from Circulating Resting CD4 ⁺ T Cells. <i>Journal of Virology</i> , 2011, 85, 5220-5223.	1.5	78
111	A Randomized Trial of 2 Different 4-Drug Antiretroviral Regimens versus a 3-Drug Regimen, in Advanced Human Immunodeficiency Virus Disease. <i>Journal of Infectious Diseases</i> , 2003, 188, 625-634.	1.9	77
112	Incidence and Clinical Features of Cerebrovascular Disease Among HIV-Infected Adults in the Southeastern United States. <i>AIDS Research and Human Retroviruses</i> , 2013, 29, 1068-1074.	0.5	75
113	Randomised trial of MNrpg120 HIV-1 vaccine in symptomless HIV-1 infection. <i>Lancet, The</i> , 1996, 348, 1547-1551.	6.3	74
114	A comparison of stavudine, didanosine and indinavir with zidovudine, lamivudine and indinavir for the initial treatment of HIV-1 infected individuals: Selection of thymidine analog regimen therapy (START) Tj ETQq0 0 0 rgt /Overlock 10 Tf	0.7	73
115	CD4 count at presentation for HIV care in the United States and Canada: Are those over 50 years more likely to have a delayed presentation?. <i>AIDS Research and Therapy</i> , 2010, 7, 45.	0.7	73
116	HIV-1 Protease, Reverse Transcriptase, and Integrase Variation. <i>Journal of Virology</i> , 2016, 90, 6058-6070.	1.5	72
117	Generalizing Evidence from Randomized Trials Using Inverse Probability of Sampling Weights. <i>Journal of the Royal Statistical Society Series A: Statistics in Society</i> , 2018, 181, 1193-1209.	0.6	69
118	Cancer-Attributable Mortality Among People With Treated Human Immunodeficiency Virus Infection in North America. <i>Clinical Infectious Diseases</i> , 2017, 65, 636-643.	2.9	67
119	Cross-Sectional Detection of Acute HIV Infection: Timing of Transmission, Inflammation and Antiretroviral Therapy. <i>PLoS ONE</i> , 2011, 6, e19617.	1.1	65
120	Disparities in the Quality of HIV Care When Using US Department of Health and Human Services Indicators. <i>Clinical Infectious Diseases</i> , 2014, 58, 1185-1189.	2.9	65
121	CD4+CD8+ T Cells Represent a Significant Portion of the Anti-HIV T Cell Response to Acute HIV Infection. <i>Journal of Immunology</i> , 2012, 188, 4289-4296.	0.4	63
122	HIV Infection, Immunosuppression, and Age at Diagnosis of Non-AIDS-Defining Cancers. <i>Clinical Infectious Diseases</i> , 2016, 64, ciw764.	2.9	63
123	Types of Myocardial Infarction Among Human Immunodeficiency Virus-Infected Individuals in the United States. <i>JAMA Cardiology</i> , 2017, 2, 260.	3.0	61
124	Clones of infected cells arise early in HIV-infected individuals. <i>JCI Insight</i> , 2019, 4, .	2.3	59
125	Human Immunodeficiency Virus Type 1 RNA Detected in the Central Nervous System (CNS) After Years of Suppressive Antiretroviral Therapy Can Originate from a Replicating CNS Reservoir or Clonally Expanded Cells. <i>Clinical Infectious Diseases</i> , 2019, 69, 1345-1352.	2.9	58
126	Longitudinal Dynamics of Intact HIV Proviral DNA and Outgrowth Virus Frequencies in a Cohort of Individuals Receiving Antiretroviral Therapy. <i>Journal of Infectious Diseases</i> , 2021, 224, 92-100.	1.9	57

#	ARTICLE	IF	CITATIONS
127	Oral hairy leukoplakia and oral candidiasis as predictors of HIV viral load. <i>Aids</i> , 1999, 13, 2174.	1.0	57
128	Factors associated with fewer visits for HIV primary care at a tertiary care center in the Southeastern U.S.. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2006, 18, 45-50.	0.6	56
129	Trends in Multidrug Treatment Failure and Subsequent Mortality among Antiretroviral Therapy-Experienced Patients with HIV Infection in North America. <i>Clinical Infectious Diseases</i> , 2009, 49, 1582-1590.	2.9	55
130	Expression of p16 ^{INK4a} as a biomarker of T-cell aging in HIV-infected patients prior to and during antiretroviral therapy. <i>Aging Cell</i> , 2012, 11, 916-918.	3.0	54
131	Estimation of the Standardized Risk Difference and Ratio in a Competing Risks Framework: Application to Injection Drug Use and Progression to AIDS After Initiation of Antiretroviral Therapy. <i>American Journal of Epidemiology</i> , 2015, 181, 238-245.	1.6	54
132	The effect of antiretroviral therapy on all-cause mortality, generalized to persons diagnosed with HIV in the USA, 2009-11. <i>International Journal of Epidemiology</i> , 2016, 45, 140-150.	0.9	53
133	Six-year follow-up of HIV-1-infected adults in a clinical trial of antiretroviral therapy with indinavir, zidovudine, and lamivudine. <i>Aids</i> , 2003, 17, 2345-2349.	1.0	52
134	Frequent detection of acute HIV infection in pregnant women. <i>Aids</i> , 2007, 21, 2303-2308.	1.0	52
135	Correlation between self-reported adherence to highly active antiretroviral therapy (HAART) and virologic outcome. <i>Advances in Therapy</i> , 2001, 18, 163-173.	1.3	51
136	Pharmacokinetic and Pharmacodynamic Investigation of Efavirenz in the Semen and Blood of Human Immunodeficiency Virus Type 1-Infected Men. <i>Journal of Infectious Diseases</i> , 2002, 186, 1339-1343.	1.9	50
137	Six-Week Randomized Controlled Trial To Compare the Tolerabilities, Pharmacokinetics, and Antiviral Activities of GW433908 and Amprenavir in Human Immunodeficiency Virus Type 1-Infected Patients. <i>Antimicrobial Agents and Chemotherapy</i> , 2004, 48, 116-123.	1.4	49
138	Immunogenicity of AGS-004 Dendritic Cell Therapy in Patients Treated During Acute HIV Infection. <i>AIDS Research and Human Retroviruses</i> , 2018, 34, 111-122.	0.5	48
139	Comparison of NucliSens and Roche Monitor Assays for Quantitation of Levels of Human Immunodeficiency Virus Type 1 RNA in Plasma. <i>Journal of Clinical Microbiology</i> , 1999, 37, 447-449.	1.8	48
140	Efficacy, safety, and adherence with a twice-daily combination lamivudine/zidovudine tablet formulation, plus a protease inhibitor, in HIV infection. <i>Aids</i> , 2000, 14, 671-681.	1.0	46
141	Association of immunosuppression and HIV viraemia with non-Hodgkin lymphoma risk overall and by subtype in people living with HIV in Canada and the USA: a multicentre cohort study. <i>Lancet HIV</i> , 2019, 6, e240-e249.	2.1	46
142	Sensitive method for the detection of infectious HIV in semen of seropositive individuals. <i>Journal of Virological Methods</i> , 1996, 56, 33-40.	1.0	45
143	Neurocognitive functioning and HAART in HIV and hepatitis C virus co-infection. <i>Aids</i> , 2006, 20, 1591-1595.	1.0	45
144	Perceived Oral Health Status, Unmet Needs, and Barriers to Dental Care Among HIV/AIDS Patients in a North Carolina Cohort: Impacts of Race. <i>Journal of Public Health Dentistry</i> , 2003, 63, 86-91.	0.5	45

#	ARTICLE	IF	CITATIONS
145	Unmet therapeutic needs in the new era of combination antiretroviral therapy for HIV-1. <i>Journal of Antimicrobial Chemotherapy</i> , 2010, 65, 1100-1107.	1.3	45
146	Brief Report: Weight Gain Following ART Initiation in ART-Naïve People Living With HIV in the Current Treatment Era. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2021, 86, 339-343.	0.9	45
147	Substance Abuse and Symptoms of Mental Illness Among HIV-positive Persons in the Southeast. <i>Southern Medical Journal</i> , 2005, 98, 9-14.	0.3	45
148	Lamivudine in combination with zidovudine, stavudine, or didanosine in patients with HIV-1 infection. A randomized, double-blind, placebo-controlled trial. <i>Aids</i> , 1999, 13, 685-694.	1.0	44
149	T-cell responses targeting HIV Nef uniquely correlate with infected cell frequencies after long-term antiretroviral therapy. <i>PLoS Pathogens</i> , 2017, 13, e1006629.	2.1	44
150	Less Bone Loss With Maraviroc- Versus Tenofovir-Containing Antiretroviral Therapy in the AIDS Clinical Trials Group A5303 Study. <i>Clinical Infectious Diseases</i> , 2015, 61, 1179-1188.	2.9	43
151	Using observational data to emulate a randomized trial of dynamic treatment-switching strategies: an application to antiretroviral therapy. <i>International Journal of Epidemiology</i> , 2016, 45, 2038-2049.	0.9	43
152	Continued Slow Decay of the Residual Plasma Viremia Level in HIV-1 Infected Adults Receiving Long-term Antiretroviral Therapy. <i>Journal of Infectious Diseases</i> , 2016, 213, 556-560.	1.9	43
153	Recent Abacavir Use Increases Risk of Type 1 and Type 2 Myocardial Infarctions Among Adults With HIV. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2018, 78, 62-72.	0.9	43
154	HIV-1 genotype and phenotype correlate with virological response to abacavir, amprenavir and efavirenz in treatment-experienced patients. <i>Aids</i> , 2002, 16, 387-396.	1.0	42
155	Primer ID Informs Next-Generation Sequencing Platforms and Reveals Preexisting Drug Resistance Mutations in the HIV-1 Reverse Transcriptase Coding Domain. <i>AIDS Research and Human Retroviruses</i> , 2015, 31, 658-668.	0.5	41
156	T cells establish and maintain CNS viral infection in HIV-infected humanized mice. <i>Journal of Clinical Investigation</i> , 2018, 128, 2862-2876.	3.9	41
157	Moving Forward in HIV-Associated Cancer. <i>Journal of Clinical Oncology</i> , 2014, 32, 876-880.	0.8	40
158	HIV-specific T cell responses reflect substantive in vivo interactions with antigen despite long-term therapy. <i>JCI Insight</i> , 2021, 6, .	2.3	40
159	Transmitted antiretroviral drug resistance among acute and recent HIV infections in North Carolina from 1998 to 2007. <i>Antiviral Therapy</i> , 2009, 14, 673-678.	0.6	40
160	Population Pharmacokinetics of Lamivudine in Adult Human Immunodeficiency Virus-Infected Patients Enrolled in Two Phase III Clinical Trials. <i>Antimicrobial Agents and Chemotherapy</i> , 1999, 43, 3025-3029.	1.4	39
161	Enrollment, Retention, and Visit Attendance in the University of North Carolina Center for AIDS Research HIV Clinical Cohort, 2001-2007. <i>AIDS Research and Human Retroviruses</i> , 2010, 26, 875-881.	0.5	39
162	HIV Viremia and Incidence of Non-Hodgkin Lymphoma in Patients Successfully Treated With Antiretroviral Therapy. <i>Clinical Infectious Diseases</i> , 2014, 58, 1599-1606.	2.9	39

#	ARTICLE	IF	CITATIONS
163	Hypertension Among HIV-infected Patients in Clinical Care, 1996–2013. <i>Clinical Infectious Diseases</i> , 2016, 63, 242-248.	2.9	39
164	HIV primary care providers’ Screening, knowledge, attitudes and behaviors related to alcohol interventions. <i>Drug and Alcohol Dependence</i> , 2016, 161, 59-66.	1.6	39
165	Evidence of Ongoing Immune Reconstitution in Subjects with Sustained Viral Suppression following 6 Years of Lopinavir-Ritonavir Treatment. <i>Clinical Infectious Diseases</i> , 2007, 44, 749-754.	2.9	38
166	Age at Antiretroviral Therapy Initiation Predicts Immune Recovery, Death, and Loss to Follow-Up Among HIV-Infected Adults in Urban Zambia. <i>AIDS Research and Human Retroviruses</i> , 2014, 30, 949-955.	0.5	38
167	Advanced immunosuppression at entry to HIV care in the southeastern United States and associated risk factors. <i>Aids</i> , 2006, 20, 775-778.	1.0	36
168	Age at Entry Into Care, Timing of Antiretroviral Therapy Initiation, and 10-Year Mortality Among HIV-Seropositive Adults in the United States. <i>Clinical Infectious Diseases</i> , 2015, 61, 1189-1195.	2.9	36
169	Triple-class antiretroviral drug resistance: risk and predictors among HIV-1-infected patients. <i>Aids</i> , 2007, 21, 825-834.	1.0	35
170	Effect of pulmonary tuberculosis on mortality in patients receiving HAART. <i>Aids</i> , 2009, 23, 707-715.	1.0	35
171	Barriers and facilitators to HIV testing and linkage to primary care: narratives of people with advanced HIV in the Southeast. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2009, 21, 1313-1320.	0.6	35
172	Lymphoma Immune Reconstitution Inflammatory Syndrome in the Center for AIDS Research Network of Integrated Clinical Systems Cohort. <i>Clinical Infectious Diseases</i> , 2014, 59, 279-286.	2.9	35
173	Failure of lopinavir–ritonavir (Kaletra)-containing regimen in an antiretroviral-naive patient. <i>Aids</i> , 2004, 18, 1084-1085.	1.0	34
174	Risk Factors for Tuberculosis After Highly Active Antiretroviral Therapy Initiation in the United States and Canada: Implications for Tuberculosis Screening. <i>Journal of Infectious Diseases</i> , 2011, 204, 893-901.	1.9	33
175	Acute HIV-1 Infection in the Southeastern United States: A Cohort Study. <i>AIDS Research and Human Retroviruses</i> , 2013, 29, 121-128.	0.5	33
176	Ten-year Survival by Race/Ethnicity and Sex Among Treated, HIV-infected Adults in the United States. <i>Clinical Infectious Diseases</i> , 2015, 60, 1700-1707.	2.9	33
177	Advances in antiretroviral therapy. <i>Current Opinion in HIV and AIDS</i> , 2013, 8, 1.	1.5	32
178	HIV-Specific, Ex Vivo Expanded T Cell Therapy: Feasibility, Safety, and Efficacy in ART-Suppressed HIV-Infected Individuals. <i>Molecular Therapy</i> , 2018, 26, 2496-2506.	3.7	32
179	Week 96 efficacy and safety results of the phase 3, randomized EMERALD trial to evaluate switching from boosted-protease inhibitors plus emtricitabine/tenofovir disoproxil fumarate regimens to the once daily, single-tablet regimen of darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) in treatment-experienced, virologically-suppressed adults living with HIV-1. <i>Antiviral Research</i> , 2019, 170, 104543.	1.9	32
180	Assessing the impact of AGS-004, a dendritic cell-based immunotherapy, and vorinostat on persistent HIV-1 Infection. <i>Scientific Reports</i> , 2020, 10, 5134.	1.6	32

#	ARTICLE	IF	CITATIONS
181	Detectable HIV-1 RNA at levels below quantifiable limits by Amplicor HIV-1 Monitor is associated with virologic relapse on antiretroviral therapy. <i>Aids</i> , 1999, 13, 1337-1342.	1.0	31
182	Changes in Clinical Context for Kaposi's Sarcoma and Non-Hodgkin Lymphoma Among People With HIV Infection in the United States. <i>Journal of Clinical Oncology</i> , 2016, 34, 3276-3283.	0.8	31
183	Cabotegravir Is Not Associated With Weight Gain in Human Immunodeficiency Virus-uninfected Individuals in HPTN 077. <i>Clinical Infectious Diseases</i> , 2020, 70, 319-322.	2.9	31
184	Mortality Among Persons Entering HIV Care Compared With the General U.S. Population. <i>Annals of Internal Medicine</i> , 2021, 174, 1197-1206.	2.0	31
185	Influence of Substance Use Disorders on 2-Year HIV Care Retention in the United States. <i>AIDS and Behavior</i> , 2018, 22, 742-751.	1.4	30
186	Week 96 results of a phase 3 trial of darunavir/cobicistat/emtricitabine/tenofovir alafenamide in treatment-naive HIV-1 patients. <i>Aids</i> , 2020, 34, 707-718.	1.0	30
187	Attrition among Human Immunodeficiency Virus (HIV)- Infected Patients Initiating Antiretroviral Therapy in China, 2003-2010. <i>PLoS ONE</i> , 2012, 7, e39414.	1.1	30
188	Hepatitis C Virus (HCV) NS3 Sequence Diversity and Antiviral Resistance-Associated Variant Frequency in HCV/HIV Coinfection. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 6079-6092.	1.4	29
189	Potential Impact of Antiretroviral Therapy and Screening on Cervical Cancer Mortality in HIV-Positive Women in Sub-Saharan Africa: A Simulation. <i>PLoS ONE</i> , 2011, 6, e18527.	1.1	28
190	Comparison of Illumina and 454 Deep Sequencing in Participants Failing Raltegravir-Based Antiretroviral Therapy. <i>PLoS ONE</i> , 2014, 9, e90485.	1.1	27
191	African American Race and HIV Virological Suppression: Beyond Disparities in Clinic Attendance. <i>American Journal of Epidemiology</i> , 2014, 179, 1484-1492.	1.6	27
192	Real-world efficacy of direct acting antiviral therapies in patients with HIV/HCV. <i>PLoS ONE</i> , 2020, 15, e0228847.	1.1	27
193	<i>Pneumocystis</i> and Severe Acute Respiratory Syndrome Coronavirus 2 Coinfection: A Case Report and Review of an Emerging Diagnostic Dilemma. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofaa633.	0.4	27
194	Correspondence between the effect of zidovudine plus lamivudine on plasma HIV level/CD4 lymphocyte count and the incidence of clinical disease in infected individuals. <i>Aids</i> , 1997, 11, 169-175.	1.0	26
195	Characterizing the Human Immunodeficiency Virus Care Continuum Among Transgender Women and Cisgender Women and Men in Clinical Care: A Retrospective Time-series Analysis. <i>Clinical Infectious Diseases</i> , 2020, 70, 1131-1138.	2.9	26
196	Prolonged therapy with the fusion inhibitor T-20 in combination with oral antiretroviral agents in an HIV-infected individual. <i>Aids</i> , 1999, 13, 2171.	1.0	26
197	Ongoing HIV Transmission and the HIV Care Continuum in North Carolina. <i>PLoS ONE</i> , 2015, 10, e0127950.	1.1	26
198	Inhibition of Human Immunodeficiency Virus Type 1 Replication In Vitro by the Bisheteroaryl piperazine Atevidine (U-87201E) in Combination with Zidovudine or Didanosine. <i>Journal of Infectious Diseases</i> , 1993, 168, 318-326.	1.9	25

#	ARTICLE	IF	CITATIONS
199	Pharmacokinetic Study of Human Immunodeficiency Virus Protease Inhibitors Used in Combination with Amprenavir. <i>Antimicrobial Agents and Chemotherapy</i> , 2001, 45, 3663-3668.	1.4	25
200	Addition of 7 Days of Zidovudine Plus Lamivudine to Peripartum Single-Dose Nevirapine Effectively Reduces Nevirapine Resistance Postpartum in HIV-Infected Mothers in Malawi. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2010, 54, 515-523.	0.9	25
201	Changes in HIV-1 Subtypes B and C Genital Tract RNA in Women and Men After Initiation of Antiretroviral Therapy. <i>Clinical Infectious Diseases</i> , 2013, 57, 290-297.	2.9	25
202	Managing Antiretroviral Therapy: Changing Regimens, Resistance Testing, and the Risks from Structured Treatment Interruptions. <i>Journal of Infectious Diseases</i> , 2008, 197, S261-S271.	1.9	24
203	Factors Associated With Severity of COVID-19 Disease in a Multicenter Cohort of People With HIV in the United States, March–December 2020. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2022, 90, 369-376.	0.9	24
204	Intracellular Nucleoside Triphosphate Concentrations in HIV-Infected Patients on Dual Nucleoside Reverse Transcriptase Inhibitor Therapy. <i>Antiviral Therapy</i> , 2007, 12, 981-986.	0.6	24
205	Short-term safety and pharmacodynamics of amdoxovir in HIV-infected patients. <i>Aids</i> , 2005, 19, 1607-1615.	1.0	23
206	Safety, Tolerability, and Efficacy of Raltegravir in a Diverse Cohort of HIV-Infected Patients: 48-Week Results from the REALMRK Study. <i>AIDS Research and Human Retroviruses</i> , 2013, 29, 859-870.	0.5	23
207	Incomplete viral suppression and mortality in HIV patients after antiretroviral therapy initiation. <i>Aids</i> , 2017, 31, 1989-1997.	1.0	23
208	Randomized Clinical Trial to Assess the Impact of the Broadly Neutralizing HIV-1 Monoclonal Antibody VRC01 on HIV-1 Persistence in Individuals on Effective ART. <i>Open Forum Infectious Diseases</i> , 2018, 5, ofy242.	0.4	23
209	Treatment Responses in Antiretroviral Treatment–Naïve Premenopausal and Postmenopausal HIV-Infected Women: An Analysis from AIDS Clinical Trials Group Studies. <i>Clinical Infectious Diseases</i> , 2009, 49, 473-476.	2.9	22
210	Rising prevalence of non-B HIV-1 subtypes in North Carolina and evidence for local onward transmission. <i>Virus Evolution</i> , 2017, 3, vex013.	2.2	22
211	Mortality following myocardial infarction among HIV-infected persons: the Center for AIDS Research Network Of Integrated Clinical Systems (CNICS). <i>BMC Medicine</i> , 2019, 17, 149.	2.3	22
212	Safety of elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide in HIV-1-infected adults with end-stage renal disease on chronic haemodialysis: an open-label, single-arm, multicentre, phase 3b trial. <i>Lancet HIV</i> , 2019, 6, e15-e24.	2.1	22
213	Impact of Biological Sex on Immune Activation and Frequency of the Latent HIV Reservoir During Suppressive Antiretroviral Therapy. <i>Journal of Infectious Diseases</i> , 2020, 222, 1843-1852.	1.9	22
214	Stable Latent HIV Infection and Low-level Viremia Despite Treatment With the Broadly Neutralizing Antibody VRC07-523LS and the Latency Reversal Agent Vorinostat. <i>Journal of Infectious Diseases</i> , 2022, 225, 856-861.	1.9	22
215	Does HAART Efficacy Translate to Effectiveness? Evidence for a Trial Effect. <i>PLoS ONE</i> , 2011, 6, e21824.	1.1	22
216	Chagasic Encephalitis as the Initial Manifestation of AIDS. <i>Annals of Internal Medicine</i> , 2006, 144, 941.	2.0	21

#	ARTICLE	IF	CITATIONS
217	Social support and delays seeking care after HIV diagnosis, North Carolina, 2000â€“2006. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2009, 21, 1148-1156.	0.6	21
218	T cells with high PD-1 expression are associated with lower HIV-specific immune responses despite long-term antiretroviral therapy. <i>Aids</i> , 2020, 34, 15-24.	1.0	21
219	HIV Cure Strategies: How Good Must They Be to Improve on Current Antiretroviral Therapy?. <i>PLoS ONE</i> , 2014, 9, e113031.	1.1	21
220	Continued lamivudine versus delavirdine in combination with indinavir and zidovudine or stavudine in lamivudine-experienced patients: results of Adult AIDS Clinical Trials Group protocol 370. <i>Aids</i> , 2000, 14, 1553-1561.	1.0	20
221	Emotional Distress in African American Women with HIV. <i>Journal of Prevention and Intervention in the Community</i> , 2007, 33, 35-50.	0.5	20
222	Severe Postvaccinia Encephalitis with Acute Disseminated Encephalomyelitis: Recovery with Early Intravenous Immunoglobulin, Highâ€Dose Steroids, and Vaccinia Immunoglobulin. <i>Clinical Infectious Diseases</i> , 2009, 48, e47-e49.	2.9	20
223	Predictors of residual viremia in patients on long-term suppressive antiretroviral therapy. <i>Antiviral Therapy</i> , 2012, 18, 39-43.	0.6	20
224	HIV risk behaviors and sociodemographic features of HIV-infected Latinos residing in a new Latino settlement area in the Southeastern United States. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2013, 25, 1298-1307.	0.6	20
225	HIV Transmission Patterns Among Immigrant Latinos Illuminated by the Integration of Phylogenetic and Migration Data. <i>AIDS Research and Human Retroviruses</i> , 2015, 31, 973-980.	0.5	20
226	Virologic outcomes in early antiretroviral treatment: HPTN 052. <i>HIV Clinical Trials</i> , 2017, 18, 100-109.	2.0	20
227	Leveraging Phylogenetics to Understand HIV Transmission and Partner Notification Networks. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2018, 78, 367-375.	0.9	20
228	Effects of Formulation and Dosing Strategy on Amprenavir Concentrations in the Seminal Plasma of Human Immunodeficiency Virus Type 1â€Infected Men. <i>Clinical Infectious Diseases</i> , 2002, 35, 760-762.	2.9	19
229	The Role of At-Risk Alcohol/Drug Use and Treatment in Appointment Attendance and Virologic Suppression Among HIV⁺ African Americans. <i>AIDS Research and Human Retroviruses</i> , 2014, 30, 233-240.	0.5	19
230	Impact of Abstinence and of Reducing Illicit Drug Use Without Abstinence on Human Immunodeficiency Virus Viral Load. <i>Clinical Infectious Diseases</i> , 2020, 70, 867-874.	2.9	19
231	Clinical Presentation, Treatment, and Outcomes Among 65 Patients with HIV-Associated Lymphoma Treated at the University of North Carolina, 2000â€“2010. <i>AIDS Research and Human Retroviruses</i> , 2012, 28, 798-805.	0.5	18
232	Associations of T cell activation and inflammatory biomarkers with virological response to darunavir/ritonavir plus raltegravir therapy. <i>Journal of Antimicrobial Chemotherapy</i> , 2013, 68, 1857-1861.	1.3	18
233	US Black Women and Human Immunodeficiency Virus Prevention: Time for New Approaches to Clinical Trials. <i>Clinical Infectious Diseases</i> , 2017, 65, 324-327.	2.9	18
234	Hospitalization Rates and Outcomes Among Persons Living With Human Immunodeficiency Virus in the Southeastern United States, 1996â€“2016. <i>Clinical Infectious Diseases</i> , 2020, 71, 1616-1623.	2.9	18

#	ARTICLE	IF	CITATIONS
235	Loss to Clinic and Five-Year Mortality among HIV-Infected Antiretroviral Therapy Initiators. PLoS ONE, 2014, 9, e102305.	1.1	18
236	Envelope diversity, coreceptor usage and syncytium-inducing phenotype of HIV-1 variants in saliva and blood during primary infection. Aids, 2003, 17, 2025-2033.	1.0	17
237	Naïve T Cells Are Maintained in the Periphery During the First 3 Months of Acute HIV-1 Infection: Implications for Analysis of Thymus Function. Journal of Clinical Immunology, 2005, 25, 462-472.	2.0	17
238	HIV-1 Protease Inhibitors and Clinical Malaria: a Secondary Analysis of the AIDS Clinical Trials Group A5208 Study. Antimicrobial Agents and Chemotherapy, 2012, 56, 995-1000.	1.4	17
239	High-Dose Lopinavir/Ritonavir in Highly Treatment-Experienced HIV-1 Patients: Efficacy, Safety, and Predictors of Response. HIV Clinical Trials, 2007, 8, 193-204.	2.0	16
240	High prevalence of cervical squamous intraepithelial lesions in women on antiretroviral therapy in Cameroon: Is targeted screening feasible?. Cancer Epidemiology, 2012, 36, 263-269.	0.8	16
241	HIV Salvage Therapy Does Not Require Nucleoside Reverse Transcriptase Inhibitors. Annals of Internal Medicine, 2015, 163, 908-917.	2.0	16
242	Cumulative Antiretroviral Exposure Measured in Hair Is Not Associated With Measures of HIV Persistence or Inflammation Among Individuals on Suppressive ART. Journal of Infectious Diseases, 2018, 218, 234-238.	1.9	16
243	Virologic suppression and CD4+ cell count recovery after initiation of raltegravir or efavirenz-containing HIV treatment regimens. Aids, 2018, 32, 261-266.	1.0	16
244	Outpatient Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 Infection to Prevent Coronavirus Disease 2019 Progression. Clinical Infectious Diseases, 2021, 73, 1717-1721.	2.9	16
245	Ending the evidence gap for pregnancy, HIV and co-infections: ethics guidance from the PHASES project. Journal of the International AIDS Society, 2021, 24, e25846.	1.2	16
246	Major Coexisting Human Immunodeficiency Virus Type 1 <i>env</i> Gene Subpopulations in the Peripheral Blood Are Produced by Cells with Similar Turnover Rates and Show Little Evidence of Genetic Compartmentalization. Journal of Virology, 2009, 83, 4068-4080.	1.5	15
247	Sexually Transmitted Infections Among Patients With Acute HIV in North Carolina. Sexually Transmitted Diseases, 2009, 36, 372-374.	0.8	15
248	Raltegravir Pharmacokinetics in Treatment-Naive Patients Is Not Influenced by Race: Results from the Raltegravir Early Therapy in African-Americans Living with HIV (REAL) Study. Antimicrobial Agents and Chemotherapy, 2013, 57, 784-788.	1.4	15
249	Elevated AST-to-platelet ratio index is associated with increased all-cause mortality among HIV-infected adults in Zambia. Liver International, 2015, 35, 1886-1892.	1.9	15
250	Validation of Medicaid Claims-based Diagnosis of Myocardial Infarction Using an HIV Clinical Cohort. Medical Care, 2015, 53, e41-e48.	1.1	15
251	Prevalence and Transmission Dynamics of HIV-1 Transmitted Drug Resistance in a Southeastern Cohort. Open Forum Infectious Diseases, 2018, 5, ofy178.	0.4	15
252	Physical activity trends and metabolic health outcomes in people living with HIV in the US, 2008-2015. Progress in Cardiovascular Diseases, 2020, 63, 170-177.	1.6	15

#	ARTICLE	IF	CITATIONS
253	Drug and alcohol use among people living with HIV in care in the United States by geographic region. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2021, 33, 1569-1576.	0.6	15
254	Performance characteristics of the CaviDx ExaVir viral load assay and the ultra-sensitive P24 assay relative to the Roche Monitor HIV-1 RNA assay. <i>Journal of Clinical Virology</i> , 2010, 49, 198-204.	1.6	14
255	Safety and efficacy of ombitasvir - 450/r and dasabuvir and ribavirin in HCV/HIV-1 co-infected patients receiving atazanavir or raltegravir ART regimens. <i>Journal of the International AIDS Society</i> , 2014, 17, 19500.	1.2	14
256	Incident AIDS or Death After Initiation of Human Immunodeficiency Virus Treatment Regimens Including Raltegravir or Efavirenz Among Adults in the United States. <i>Clinical Infectious Diseases</i> , 2017, 64, 1591-1596.	2.9	14
257	Analysis of Virological Efficacy in Trials of Antiretroviral Regimens: Drawbacks of Not Including Viral Load Measurements after Premature Discontinuation of Therapy. <i>Antiviral Therapy</i> , 2002, 7, 271-281.	0.6	14
258	Determination of amprenavir, a HIV-1 protease inhibitor, in human seminal plasma using high-performance liquid chromatography-tandem mass spectrometry. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2002, 766, 307-317.	1.2	13
259	Survival in Women Exposed to Single-Dose Nevirapine for Prevention of Mother-to-Child Transmission of HIV: A Stochastic Model. <i>Journal of Infectious Diseases</i> , 2007, 195, 837-846.	1.9	13
260	Incident Sexually Transmitted Infection as a Biomarker for High-Risk Sexual Behavior After Diagnosis of Acute HIV. <i>Sexually Transmitted Diseases</i> , 2014, 41, 447-452.	0.8	13
261	Large scale screening of human sera for HCV RNA and GBV-C RNA. <i>Journal of Medical Virology</i> , 2014, 86, 473-477.	2.5	13
262	Evaluating the Population Impact on Racial/Ethnic Disparities in HIV in Adulthood of Intervening on Specific Targets: A Conceptual and Methodological Framework. <i>American Journal of Epidemiology</i> , 2018, 187, 316-325.	1.6	13
263	Emulating a trial of joint dynamic strategies: An application to monitoring and treatment of HIV-positive individuals. <i>Statistics in Medicine</i> , 2019, 38, 2428-2446.	0.8	13
264	Brief Report: No Evidence for an Association Between Statin Use and Lower Biomarkers of HIV Persistence or Immune Activation/Inflammation During Effective ART. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2019, 82, e27-e31.	0.9	13
265	The Frequency of Malaria Is Similar among Women Receiving either Lopinavir/Ritonavir or Nevirapine-based Antiretroviral Treatment. <i>PLoS ONE</i> , 2012, 7, e34399.	1.1	13
266	Discontinuation Rates for Protease Inhibitor Regimens Containing Ritonavir 600 mg versus Ritonavir 400 mg Plus Saquinavir 400 mg. <i>Annals of Pharmacotherapy</i> , 1999, 33, 899-905.	0.9	12
267	Self-report of current and prior antiretroviral drug use in comparison to the medical record among HIV-infected patients receiving primary HIV care. <i>Pharmacoepidemiology and Drug Safety</i> , 2011, 20, 432-439.	0.9	12
268	Evaluating the Effect of Early Versus Late ARV Regimen Change if Failure on an Initial Regimen: Results From the AIDS Clinical Trials Group Study A5095. <i>Journal of the American Statistical Association</i> , 2012, 107, 542-554.	1.8	12
269	Hepatic safety and tolerability of raltegravir among HIV patients coinfecting with hepatitis B and/or C. <i>Antiviral Therapy</i> , 2014, 19, 415-422.	0.6	12
270	Regimen selection in the OPTIONS trial of HIV salvage therapy: drug resistance, prior therapy, and race-ethnicity determine the degree of regimen complexity. <i>HIV Clinical Trials</i> , 2015, 16, 147-156.	2.0	12

#	ARTICLE	IF	CITATIONS
271	Identifying HIV care enrollees at-risk for cannabis use disorder. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2017, 29, 846-850.	0.6	12
272	Not all non-drinkers with HIV are equal: demographic and clinical comparisons among current non-drinkers with and without a history of prior alcohol use disorders [*] . <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2017, 29, 177-184.	0.6	12
273	The Role of Current and Historical Alcohol Use in Hepatic Fibrosis Among HIV-Infected Individuals. <i>AIDS and Behavior</i> , 2017, 21, 1878-1884.	1.4	12
274	Virologic Failure Among People Living With HIV Initiating Dolutegravir-Based Versus Other Recommended Regimens in Real-World Clinical Care Settings. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2019, 81, 572-577.	0.9	12
275	Brief Report: HIV Antibodies Decline During Antiretroviral Therapy but Remain Correlated With HIV DNA and HIV-Specific T-Cell Responses. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2019, 81, 594-599.	0.9	12
276	Hospitalization Rates and Causes Among Persons With HIV in the United States and Canada, 2005â€“2015. <i>Journal of Infectious Diseases</i> , 2021, 223, 2113-2123.	1.9	12
277	Effect of hepatitis C coinfection on discontinuation and modification of initial HAART in primary HIV care. <i>Aids</i> , 2006, 20, 575-583.	1.0	11
278	HIV-1 viral load and phenotypic antiretroviral drug resistance assays based on reverse transcriptase activity in comparison to amplification based HIV-1 RNA and genotypic assays. <i>Journal of Clinical Virology</i> , 2010, 47, 18-22.	1.6	11
279	The Design of Single-Arm Clinical Trials of Combination Antiretroviral Regimens for Treatment-Naive HIV-Infected Patients. <i>AIDS Research and Human Retroviruses</i> , 2013, 29, 652-657.	0.5	11
280	Genetic architecture of cardiometabolic risks in people living with HIV. <i>BMC Medicine</i> , 2020, 18, 288.	2.3	11
281	Dose Separation Does Not Overcome the Pharmacokinetic Interaction between Fosamprenavir and Lopinavir/Ritonavir. <i>Antimicrobial Agents and Chemotherapy</i> , 2006, 50, 2756-2761.	1.4	10
282	Association of Efavirenz Hypersusceptibility with Virologic Response in ACTG 368, a Randomized Trial of Abacavir (ABC) in Combination with Efavirenz (EFV) and Indinavir (IDV) in HIV-Infected Subjects with Prior Nucleoside Analog Experience. <i>HIV Clinical Trials</i> , 2008, 9, 11-25.	2.0	10
283	Variability of the Date of HIV Diagnosis: A Comparison of Self-Report, Medical Record, and HIV/AIDS Surveillance Data. <i>Annals of Epidemiology</i> , 2010, 20, 734-742.	0.9	10
284	Increased Cortical Cerebral Blood Flow in Asymptomatic Human Immunodeficiency Virus-Infected Subjects. <i>Journal of Stroke and Cerebrovascular Diseases</i> , 2016, 25, 1891-1895.	0.7	10
285	Comparison of dynamic monitoring strategies based on CD4 cell counts in virally suppressed, HIV-positive individuals on combination antiretroviral therapy in high-income countries: a prospective, observational study. <i>Lancet HIV</i> , 2017, 4, e251-e259.	2.1	10
286	Brief Report: Longitudinal Opioid Use Among HIV-Infected Patients, 2000 to 2014. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2017, 75, 77-80.	0.9	10
287	Risk factors for delayed antiretroviral therapy initiation among HIV-seropositive patients. <i>PLoS ONE</i> , 2017, 12, e0180843.	1.1	10
288	HIV Drug Resistance in Adults Receiving Early vs. Delayed Antiretroviral Therapy: HPTN 052. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2018, 77, 484-491.	0.9	10

#	ARTICLE	IF	CITATIONS
289	Brief Report: Virologic Response by Baseline Viral Load With Dolutegravir Plus Lamivudine vs Dolutegravir Plus Tenofovir Disoproxil Fumarate/Emtricitabine: Pooled Analysis. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2020, 84, 60-65.	0.9	10
290	HIV Viremia and Risk of Stroke Among People Living with HIV Who Are Using Antiretroviral Therapy. <i>Epidemiology</i> , 2021, 32, 457-464.	1.2	10
291	Higher colorectal tissue HIV infectivity in cisgender women compared with MSM before and during oral preexposure prophylaxis. <i>Aids</i> , 2021, 35, 1585-1595.	1.0	10
292	Five-Year Mortality for Adults Entering Human Immunodeficiency Virus Care Under Universal Early Treatment Compared With the General US Population. <i>Clinical Infectious Diseases</i> , 2022, 75, 867-874.	2.9	10
293	A Randomized Trial of Nelfinavir and Abacavir in Combination with Efavirenz and Adefovir Dipivoxil in HIV-1-Infected Persons with Virological Failure Receiving Indinavir. <i>Antiviral Therapy</i> , 2003, 8, 507-518.	0.6	10
294	A 42-Week Open-Label Study to Assess the Pharmacokinetics, Antiretroviral Activity, and Safety of Amprenavir or Amprenavir plus Ritonavir in Combination with Abacavir and Lamivudine for Treatment of HIV-Infected Patients. <i>Clinical Infectious Diseases</i> , 2004, 39, 591-594.	2.9	9
295	Missing Data on the Estimation of the Prevalence of Accumulated Human Immunodeficiency Virus Drug Resistance in Patients Treated With Antiretroviral Drugs in North America. <i>American Journal of Epidemiology</i> , 2011, 174, 727-735.	1.6	9
296	Unexpected Finding of Delayed-Onset Seizures in HIV-Positive, Treatment-Experienced Subjects in the Phase IIB Evaluation of Fosdevirine (Gsk2248761). <i>Antiviral Therapy</i> , 2014, 19, 69-78.	0.6	9
297	Viral suppression in HIV studies: Combining times to suppression and rebound. <i>Biometrics</i> , 2014, 70, 441-448.	0.8	9
298	Phylogenetic Evidence of HIV-1 Sequence Evolution in Subjects with Persistent Low-Level Viraemia. <i>Antiviral Therapy</i> , 2015, 20, 73-76.	0.6	9
299	R5 Macrophage-Tropic HIV-1 in the Male Genital Tract. <i>Journal of Virology</i> , 2015, 89, 10688-10692.	1.5	9
300	The Impact of Implementation Fidelity on Mortality Under a CD4-Stratified Timing Strategy for Antiretroviral Therapy in Patients With Tuberculosis. <i>American Journal of Epidemiology</i> , 2015, 181, 714-722.	1.6	9
301	Differential CD4+ cell count increase and CD4+. <i>Aids</i> , 2016, 30, 2091-2097.	1.0	9
302	Patterns of efavirenz use as first-line antiretroviral therapy in the United States: 1999-2015. <i>Antiviral Therapy</i> , 2018, 23, 363-372.	0.6	9
303	Association Between Bilirubin, Atazanavir, and Cardiovascular Disease Events Among People Living With HIV Across the United States. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2019, 81, e141-e147.	0.9	9
304	Association of Male Sex and Obesity With Residual Plasma Human Immunodeficiency Virus 1 Viremia in Persons on Long-Term Antiretroviral Therapy. <i>Journal of Infectious Diseases</i> , 2021, 223, 462-470.	1.9	9
305	Fusion designs and estimators for treatment effects. <i>Statistics in Medicine</i> , 2021, 40, 3124-3137.	0.8	9
306	Spatial Epidemiology of Recently Acquired HIV Infections across Rural and Urban Areas of North Carolina. <i>PLoS ONE</i> , 2014, 9, e88512.	1.1	9

#	ARTICLE	IF	CITATIONS
307	Outcomes of Second Combination Antiretroviral Therapy Regimens Among HIV-Infected Persons in Clinical Care: A Multicenter Cohort Study. <i>AIDS Research and Human Retroviruses</i> , 2013, 29, 574-580.	0.5	8
308	Low Prevalence of Antiretroviral Resistance Among HIV Type 1-Positive Prisoners in the Southeast United States. <i>AIDS Research and Human Retroviruses</i> , 2013, 29, 136-141.	0.5	8
309	Cancer risk in HIV patients with incomplete viral suppression after initiation of antiretroviral therapy. <i>PLoS ONE</i> , 2018, 13, e0197665.	1.1	8
310	Postpartum HIV care continuum outcomes in the southeastern USA. <i>Aids</i> , 2019, 33, 637-644.	1.0	8
311	Estimating a Set of Mortality Risk Functions with Multiple Contributing Causes of Death. <i>Epidemiology</i> , 2020, 31, 704-712.	1.2	8
312	CD4 Count at Entry into Care and at Antiretroviral Therapy Prescription among Adults with Human Immunodeficiency Virus in the United States, 2005-2018. <i>Clinical Infectious Diseases</i> , 2021, 73, e2334-e2337.	2.9	8
313	Predictive Value of Pharmacokinetics-Adjusted Phenotypic Susceptibility on Response to Ritonavir-Enhanced Protease Inhibitors (PIs) in Human Immunodeficiency Virus-Infected Subjects Failing Prior PI Therapy. <i>Antimicrobial Agents and Chemotherapy</i> , 2009, 53, 2335-2341.	1.4	7
314	Pilot study demonstrating effectiveness of targeted education to improve informed consent understanding in AIDS clinical trials. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2011, 23, 1382-1391.	0.6	7
315	Association between first-year virological response to raltegravir and long-term outcomes in treatment-experienced patients with HIV-1 infection. <i>Antiviral Therapy</i> , 2014, 20, 307-315.	0.6	7
316	Comparing neighborhood and state contexts for women living with and without HIV: understanding the Southern HIV epidemic. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2018, 30, 1360-1367.	0.6	7
317	Darunavir/cobicistat/emtricitabine/tenofovir alafenamide in treatment-experienced, virologically suppressed patients with HIV-1: subgroup analyses of the phase 3 EMERALD study. <i>AIDS Research and Therapy</i> , 2019, 16, 23.	0.7	7
318	Effect of Hydroxyurea and Dideoxyinosine on Intracellular 3'-Deoxyadenosine-5'-triphosphate Concentrations in HIV-Infected Patients. <i>AIDS Research and Human Retroviruses</i> , 2007, 23, 1360-1365.	0.5	6
319	How Researchers Define Vulnerable Populations in HIV/AIDS Clinical Trials. <i>AIDS and Behavior</i> , 2010, 14, 1313-1319.	1.4	6
320	Modeling Clinical Endpoints as a Function of Time of Switch to Second-Line ART with Incomplete Data on Switching Times. <i>Biometrics</i> , 2013, 69, 732-740.	0.8	6
321	Antiretroviral Activity and Safety of Once-Daily Etravirine in Treatment-Naive HIV-Infected Adults: 48-Week Results. <i>Antiviral Therapy</i> , 2016, 21, 55-64.	0.6	6
322	Dynamic Visual Display of Treatment Response in HIV-Infected Adults. <i>Clinical Infectious Diseases</i> , 2015, 61, e1-e4.	2.9	6
323	Associations Between At-Risk Alcohol Use, Substance Use, and Smoking with Lipohypertrophy and Lipoatrophy Among Patients Living with HIV. <i>AIDS Research and Human Retroviruses</i> , 2017, 33, 534-545.	0.5	6
324	Health Insurance Type and Control of Hypertension Among US Women Living With and Without HIV Infection in the Women's Interagency HIV Study. <i>American Journal of Hypertension</i> , 2017, 30, 594-601.	1.0	6

#	ARTICLE	IF	CITATIONS
325	Co-trimoxazole Prophylaxis, Asymptomatic Malaria Parasitemia, and Infectious Morbidity in Human Immunodeficiency Virus-Exposed, Uninfected Infants in Malawi: The BAN Study. <i>Clinical Infectious Diseases</i> , 2017, 65, 575-580.	2.9	6
326	Neighborhood Poverty and Control of HIV, Hypertension, and Diabetes in the Women's Interagency HIV Study. <i>AIDS and Behavior</i> , 2020, 24, 2033-2044.	1.4	6
327	Clinical Effectiveness of Integrase Strand Transfer Inhibitor-Based Antiretroviral Regimens Among Adults With Human Immunodeficiency Virus: A Collaboration of Cohort Studies in the United States and Canada. <i>Clinical Infectious Diseases</i> , 2020, 73, e1408-e1414.	2.9	6
328	HIV-1 Transmission linkages among persons with incident infection to inform public health surveillance. <i>EClinicalMedicine</i> , 2021, 37, 100968.	3.2	6
329	Infectious Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Virus in Symptomatic Coronavirus Disease 2019 (COVID-19) Outpatients: Host, Disease, and Viral Correlates. <i>Clinical Infectious Diseases</i> , 2022, 75, e1028-e1036.	2.9	6
330	Aciclovir Treatment for Human Immunodeficiency Virus-1: Is the "Juice Worth the Squeeze"? <i>Sexually Transmitted Diseases</i> , 2011, 38, 410-412.	0.8	5
331	Paradoxical interpretations of noninferiority studies: violating the excluded middle. <i>Future Virology</i> , 2012, 7, 1055-1063.	0.9	5
332	Sensitivity Analyses for Misclassification of Cause of Death in the Parametric G-Formula. <i>American Journal of Epidemiology</i> , 2018, 187, 1808-1816.	1.6	5
333	Predicting Efavirenz Concentrations in the Brain Tissue of HIV-Infected Individuals and Exploring their Relationship to Neurocognitive Impairment. <i>Clinical and Translational Science</i> , 2019, 12, 302-311.	1.5	5
334	Estimating Human Immunodeficiency Virus (HIV) Prevention Effects in Low-incidence Settings. <i>Epidemiology</i> , 2019, 30, 358-364.	1.2	5
335	Randomized Controlled Pilot Study of Antiretrovirals and a Behavioral Intervention for Persons With Acute HIV Infection: Opportunity for Interrupting Transmission. <i>Open Forum Infectious Diseases</i> , 2019, 6, ofy341.	0.4	5
336	Evaluating the Efficacy of Therapies in Patients With Coronavirus Disease 2019. <i>Clinical Infectious Diseases</i> , 2021, 72, 1093-1100.	2.9	5
337	Comparison of methods to quantify inducible HIV-1 outgrowth. <i>Journal of Virus Eradication</i> , 2021, 7, 100043.	0.3	5
338	Evaluation of HIV-1 reservoir size and broadly neutralizing antibody susceptibility in acute antiretroviral therapy-treated individuals. <i>Aids</i> , 2022, 36, 205-214.	1.0	5
339	Novel Criteria for Diagnosing Acute and Early Human Immunodeficiency Virus Infection in a Multinational Study of Early Antiretroviral Therapy Initiation. <i>Clinical Infectious Diseases</i> , 2021, 73, e643-e651.	2.9	5
340	Virologic outcomes among adults with HIV using integrase inhibitor-based antiretroviral therapy. <i>Aids</i> , 2022, 36, 277-286.	1.0	5
341	Natural Killer Cell Receptors and Ligands Are Associated With Markers of HIV-1 Persistence in Chronically Infected ART Suppressed Patients. <i>Frontiers in Cellular and Infection Microbiology</i> , 2022, 12, 757846.	1.8	5
342	New anti-HIV-1 therapies and combinations. <i>Aids</i> , 1990, 4, S201.	1.0	4

#	ARTICLE	IF	CITATIONS
343	A Novel Codon Insert in Protease of Clade B HIV Type 1. <i>AIDS Research and Human Retroviruses</i> , 2009, 25, 547-550.	0.5	4
344	High clade C HIV-1 viremia. <i>Aids</i> , 2011, 25, 1543-1545.	1.0	4
345	Massive CD8 T Cell Response to Primary HIV Infection in the Setting of Severe Clinical Presentation. <i>AIDS Research and Human Retroviruses</i> , 2012, 28, 789-792.	0.5	4
346	Brain neurotransmitter transporter/receptor genomics and efavirenz central nervous system adverse events. <i>Pharmacogenetics and Genomics</i> , 2018, 28, 179-187.	0.7	4
347	Efficacy, pharmacokinetics and neurocognitive performance of dual, NRTI-sparing antiretroviral therapy in acute HIV-infection. <i>Aids</i> , 2020, 34, 1923-1931.	1.0	4
348	Antiretroviral drug class and anaemia risk in the current treatment era among people living with HIV in the USA: a clinical cohort study. <i>BMJ Open</i> , 2020, 10, e031487.	0.8	4
349	Racial, ethnic, and gender disparities in hospitalizations among persons with HIV in the United States and Canada, 2005-2015. <i>Aids</i> , 2021, 35, 1229-1239.	1.0	4
350	Smoking and Predictors of Pneumonia Among HIV-Infected Patients Receiving Care in the HAART Era. <i>Open Respiratory Medicine Journal</i> , 2008, 2, 22-28.	1.3	4
351	The Safety, Plasma Pharmacokinetics, and Antiviral Activity of Subcutaneous Enfuvirtide (T-20), a Peptide Inhibitor of gp41-Mediated Virus Fusion, in HIV-Infected Adults. <i>AIDS Research and Human Retroviruses</i> , 2003, 19, 83-83.	0.5	3
352	Short Communication: Lack of Occult HIV Infection Among Non-AIDS-Defining Cancer Patients in Three Academic Oncology Clinics in the United States. <i>AIDS Research and Human Retroviruses</i> , 2013, 29, 887-891.	0.5	3
353	Effects of Health Insurance Interruption on Loss of Hypertension Control in Women With and Women Without HIV. <i>Journal of Women's Health</i> , 2017, 26, 1292-1301.	1.5	3
354	Opioid misuse among persons with HIV engaged in care in the Southeastern US. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2021, 33, 148-153.	0.6	3
355	Current and Past Immunodeficiency Are Associated With Higher Hospitalization Rates Among Persons on Virologically Suppressive Antiretroviral Therapy for up to 11 Years. <i>Journal of Infectious Diseases</i> , 2021, 224, 657-666.	1.9	3
356	Immune activation and plasma viral load in HIV-infected African individuals. <i>Aids</i> , 1999, 13, 1283.	1.0	2
357	Transcriptional Changes in CD8+ T Cells During Antiretroviral Therapy Intensified With Raltegravir. <i>Open Forum Infectious Diseases</i> , 2015, 2, ofv045.	0.4	2
358	Estimating multiple time-fixed treatment effects using a semi-Bayes semiparametric marginal structural Cox proportional hazards regression model. <i>Biometrical Journal</i> , 2018, 60, 100-114.	0.6	2
359	Differentiation of Type 1 and Type 2 Myocardial Infarctions Among HIV-Infected Patients Requires Adjudication Due to Overlap in Risk Factors. <i>AIDS Research and Human Retroviruses</i> , 2018, 34, 916-921.	0.5	2
360	Current Antiretroviral Treatment Among People With Human Immunodeficiency Virus in the United States: Findings from the Centers for AIDS Research Network of Integrated Clinic Systems Cohort. <i>Clinical Infectious Diseases</i> , 2022, 75, 715-718.	2.9	2

#	ARTICLE	IF	CITATIONS
361	Associations Between Multiple Measures of HIV-1 Persistence in Persons on Suppressive Antiretroviral Therapy. <i>Journal of Infectious Diseases</i> , 2022, 225, 2163-2166.	1.9	2
362	Quality control of HIV cultures in a clinical retrovirology laboratory. <i>Journal of Virological Methods</i> , 1996, 58, 91-98.	1.0	1
363	How clean was the KLEAN trial? "Authors' reply. <i>Lancet</i> , The, 2006, 368, 1571.	6.3	1
364	Repeat testing of low-level HIV-1 RNA. <i>Aids</i> , 2018, 32, 1053-1057.	1.0	1
365	Stable Caloric Intake and Continued Virologic Suppression for HIV-Positive Antiretroviral Treatment-Experienced Women After Switching to a Single-Tablet Regimen of Emtricitabine, Rilpivirine, and Tenofovir Disoproxil Fumarate. <i>AIDS Research and Human Retroviruses</i> , 2018, 34, 481-485.	0.5	1
366	1768. Efficacy and Safety of Switching From Boosted-Protease Inhibitors (bPI) Plus Emtricitabine/Tenofovir Disoproxil Fumarate (F/TDF) Regimens to the Once Daily (QD), Single-Tablet Regimen (STR) of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) in Virologically Suppressed, HIV-1-Infected Adults: Week 96 Results of the Phase 3, Randomized, Non-Inferiority EMERALD Trial. <i>Open Forum Infectious Diseases</i> , 2018, 5, S65-S65.	0.4	1
367	Evolution of HIV-1 drug resistance after virological failure of first-line antiretroviral therapy in Lusaka Zambia. <i>Antiviral Therapy</i> , 2019, 24, 291-300.	0.6	1
368	Prevalence and risk of residual viremia after ART in low- and middle-income countries. <i>Medicine (United States)</i> , 2021, 100, e26817.	0.4	1
369	Rapid analysis of local data to inform off-label tocilizumab use early in the COVID-19 pandemic. <i>Healthcare</i> , 2021, 9, 100581.	0.6	1
370	Unmasking Lymphoma Immune Reconstitution Inflammatory Syndrome Among HIV-Infected Individuals In The Center For AIDS Research Network Of Integrated Clinical Systems. <i>Blood</i> , 2013, 122, 4331-4331.	0.6	1
371	Reply to "pharmacokinetic concerns related to darunavir/ritonavir plus raltegravir combination therapy trial". <i>Aids</i> , 2012, 26, 397-398.	1.0	0
372	Evaluating the incident user design in the HIV population: incident use versus naive?. <i>Pharmacoepidemiology and Drug Safety</i> , 2015, 24, 297-300.	0.9	0
373	THU-135-Real-world HCV treatment in HCV-HIV coinfecting population: Data from the TRIO network. <i>Journal of Hepatology</i> , 2019, 70, e220-e221.	1.8	0
374	Short-cycle therapy is short on ethics. <i>International Journal of Antimicrobial Agents</i> , 2021, 57, 106331.	1.1	0